TY - JOUR
T1 - Bystander suppression of experimental arthritis by nasal administration of a heat shock protein peptide.
AU - Zonneveld - Huijssoon, E.
AU - Roord, S.T.A.
AU - de Jager, W.
AU - Klein, M.
AU - Albani, S.
AU - Anderton, S.M.
AU - Kuis, W.
AU - van Wijk, F.
AU - Prakken, A.B.J.
PY - 2011
Y1 - 2011
N2 - Objectives Mucosal immune therapy with disease-inducing antigens is an effective way to prevent experimental arthritis, but in humans these antigens are unknown. In juvenile idiopathic arthritis, however, T cell recognition of a so-called bystander antigen, heat shock protein 60 (HSP60), is associated with a good prognosis. Recently epitopes derived from HSP60, a microbial peptide (p1) and its self-homologue (p2) were reported to induce tolerogenic T cell responses in vitro in patients with arthritis. A study was undertaken to determine whether mucosal administration of these bystander epitopes can be similarly effective in suppressing arthritis.
AB - Objectives Mucosal immune therapy with disease-inducing antigens is an effective way to prevent experimental arthritis, but in humans these antigens are unknown. In juvenile idiopathic arthritis, however, T cell recognition of a so-called bystander antigen, heat shock protein 60 (HSP60), is associated with a good prognosis. Recently epitopes derived from HSP60, a microbial peptide (p1) and its self-homologue (p2) were reported to induce tolerogenic T cell responses in vitro in patients with arthritis. A study was undertaken to determine whether mucosal administration of these bystander epitopes can be similarly effective in suppressing arthritis.
U2 - 10.1136/ard.2010.136994
DO - 10.1136/ard.2010.136994
M3 - Article
C2 - 21914624
SN - 0003-4967
VL - 70
SP - 2199
EP - 2206
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 12
ER -